Showing results (311-320 of 2,409) with videos related to
Sort By:
Pageof 241
Journal of Medical Economics|November 1, 2011
Real-life treatment patterns, compliance, persistence, and medication costs in patients with hypertension in GermanyL Breitscheidel, B Ehlken, K Kostev, et al.Journal of Medical Economics|December 16, 2011
Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritisE J Soini, T A Hallinen, K Puolakka, et al.Journal of Medical Economics|March 1, 2012
Improving prevention and treatment of venous thromboembolism: clinical trial resultsCharles Mahan, Alex C SpyropoulosJournal of Medical Economics|January 6, 2015
The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolismAarti A Patel, Kristine Ogden, Samir H Mody, et al.Journal of Medical Economics|December 20, 2014
Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychoticsOnur Baser, Lin Xie, Jacqueline Pesa, et al.Journal of Medical Economics|March 2, 2016
The association between osteoporosis and patient outcomes in JapanLuis A Yamamoto, Marco DiBonaventura, Isao KawaguchiJournal of Medical Economics|February 25, 2016
Cost-minimization analysis of sublingual immunotherapy versus subcutaneous immunotherapy for house dust mite respiratory allergic disease in DenmarkSteen Rønborg, Claus R Johnsen, Sune Theilgaard, et al.Journal of Medical Economics|November 28, 2015
Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemiaJohn Whalen, Ipek Stillman, Apoorva Ambavane, et al.Journal of Medical Economics|November 28, 2013
Assessment of resource use and costs associated with parathyroidectomy for secondary hyperparathyroidism in end stage renal disease in the UKRhys D Pockett, Emir Cevro, George Chamberlain, et al.Journal of Medical Economics|October 18, 2013
National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plansAmie T Joyce, Shravanthi R Gandra, Kathleen M Fox, et al.Pageof 241